Clinical Trial

A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis

Study acronym: ICONIC-PsA 2
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy of icotrokinra (JNJ-77242113) compared to placebo in biologic-experienced and biologic-naive participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.
Protocol Amendment History 1 change
notable Trial sites expanded: 216 -> 224 locations 2026-07-07
Trial Details
NCT Number NCT06807424
Lead Sponsor Janssen Research & Development, LLC
Conditions Arthritis, Psoriatic
Enrollment 750 participants
Start Date 2025-01-09
Primary Completion 2027-02-10 (estimated)
Study Completion 2028-10-18 (estimated)
Updated on ClinicalTrials.gov 2026-07-06